跳转至内容
Merck
CN

B8312

BNTX maleate salt hydrate

≥98% (HPLC)

别名:

7(E)-Benzylidenenaltrexone maleate salt hydrate, BNTX-7 maleate salt hydrate, Morphinan-6-one,17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-7-(phenylmethylene)-,(5a,7E)- maleate salt hydrate

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C31H31NO8 · xH2O
分子量:
545.58 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329773306
UNSPSC Code:
12352200
MDL number:
MFCD12912399
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

AGUNLJBLOJAUKM-ZKJXOIBSSA-N

SMILES string

O.OC(=O)\C=C/C(O)=O.Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c6ccccc6)CC7CC7

InChI

1S/C27H27NO4.C4H4O4.H2O/c29-20-9-8-18-13-21-27(31)14-19(12-16-4-2-1-3-5-16)23(30)25-26(27,22(18)24(20)32-25)10-11-28(21)15-17-6-7-17;5-3(6)1-2-4(7)8;/h1-5,8-9,12,17,21,25,29,31H,6-7,10-11,13-15H2;1-2H,(H,5,6)(H,7,8);1H2/b19-12+;2-1-;/t21-,25+,26+,27-;;/m1../s1

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

yellow

solubility

DMSO: >20 mg/mL

storage temp.

−20°C

Quality Level

100

Application

BNTX, a selective nonpeptide σ1 opioid receptor (DOR1) antagonist, is used in σ opioid receptor research to help differentiate and characterized the function and role of the σ1 opioid receptor versus other σ opioid receptor subtypes. BNTX was used to help define the role of σ1 opioid receptors in neurological processes such as anxiety. It was used to help define the role of σ opioid receptors in myocardial infarct development and size.

Biochem/physiol Actions

BNTX is a selective d1 non peptide opioid receptor antagonist.
BNTX is a selective nonpeptide δ1 opioid receptor antagonist. It antagonizes the effect of D-Pen2,5-enkephalin (a δ1 agonist 4-6 fold, but did not affect the activity of δ2 or μ agonists.<<<107>>> BNTX is used to discriminate among opioid receptor subtypes in effects such as alcohol and drug dependence. It binds 100× more tightly to δ1 than to δ2 receptors. In the tail-flick assay, antinocieceptive ED50 = 646.4 pmol/mouse.

Features and Benefits

This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

hcodes

H319,H400

Hazard Classifications

Aquatic Acute 1 - Eye Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000487320
0000487318
0000487320
0000487318
024M4607V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Garrett J Gross et al.
Journal of cardiovascular pharmacology, 59(2), 194-197 (2011-12-02)
Eribis peptide 94 (EP 94) is a novel enkephalin derivative that binds with high potency to μ and δ opioid receptors with less affinity for the κ opioid receptor. This compound has recently been shown to produce an acute reduction
Yoshinori Miyata et al.
Bioorganic & medicinal chemistry letters, 21(16), 4710-4712 (2011-07-19)
We evaluated antimalarial and/or chloroquine-resistance reversing effects of five opioid receptor antagonists. Although none of the evaluated compounds showed antimalarial effects, some of them, especially the δ(1) receptor antagonist, 7-benzylidenenaltrexone (BNTX) exhibited potent chloroquine-resistance reversing effects in Plasmodium chabaudi.
Azusa Sugiyama et al.
Neuropharmacology, 79, 314-320 (2013-12-18)
Recently, we reported that the δ opioid receptor (DOR) agonist KNT-127 produces anxiolytic-like effects in behaving rats. Here, we report on the roles of DOR subtypes ( DOR(1) and DOR(2)) play in mediating KNT-127-induced anxiolytic-like effects. Pretreatment with the DOR(2)-selective
So Young Kim et al.
Oncotarget, 8(37), 61057-61071 (2017-10-06)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential biological anticancer agent. However, a wide range of human primary cancers, including pancreatic cancer, display resistance to apoptosis induction by TRAIL. Therefore, this resistance needs to be overcome to allow TRAIL

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持